SEC Stock Data Quick Answer X4 Pharmaceuticals, Inc reported Revenue (ASC 606) of $35.11 million for fiscal year 2025. X4 Pharmaceuticals, Inc Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $35.11M +1273.2% 2024 $2.56M — 2023 $0.00 — 2022 $0.00 — 2021 $0.00 -100.0% 2020 $3.00M — 2019 $0.00 — 2018 $0.00 … Read more
Quick Answer X4 Pharmaceuticals, Inc reported Total Revenue of $35.11 million for fiscal year 2025. X4 Pharmaceuticals, Inc Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $35.11M +1273.2% 2024 $2.56M — 2023 $0.00 — 2022 $0.00 — 2021 $0.00 -100.0% 2020 $3.00M — 2019 $0.00 — 2018 $0.00 — Quarterly Total … Read more
Quick Answer X4 Pharmaceuticals, Inc reported Total Revenue of $35.11 million for fiscal year 2025. X4 Pharmaceuticals, Inc — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $35.11M+1273.2% $2.56M $0.00 $0.00 $0.00-100.0% $3.00M Revenue (ASC 606) $35.11M+1273.2% $2.56M $0.00 $0.00 $0.00-100.0% $3.00M Net Income -$79.20M-111.5% -$37.45M+63.0% -$101.17M-7.8% -$93.87M-5.8% -$88.70M-42.8% -$62.13M-17.7% … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Shares Outstanding of 166.22 million shares for fiscal year 2025. Xeris Biopharma Holdings, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 166.22M +11.2% 2024 149.43M +8.2% 2023 138.13M +1.4% 2022 136.27M +9.1% 2021 124.87M — Quarterly Shares Outstanding Quarter Ending Shares Outstanding YoY … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Operating Income of $24.90 million for fiscal year 2025. Xeris Biopharma Holdings, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 $24.90M +174.0% 2024 -$33.65M +23.5% 2023 -$44.01M +46.3% 2022 -$81.94M +28.8% 2021 -$115.16M -37.8% 2020 -$83.55M — Quarterly Operating Income Quarter Ending Operating … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported R&D Expense of $31.16 million for fiscal year 2025. Xeris Biopharma Holdings, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $31.16M +21.9% 2024 $25.56M +14.4% 2023 $22.34M +6.6% 2022 $20.97M -16.7% 2021 $25.16M +20.3% 2020 $20.92M — Quarterly R&D Expense Quarter Ending R&D … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Stockholders Equity of $13.69 million for fiscal year 2025. Xeris Biopharma Holdings, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $13.69M +146.2% 2024 -$29.61M -336.7% 2023 -$6.78M -115.0% 2022 $45.19M -52.6% 2021 $95.23M +182.1% 2020 $33.76M +133.9% 2019 $14.44M — Quarterly Stockholders Equity … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Long-Term Debt of $220.34 million for fiscal year 2025. Xeris Biopharma Holdings, Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $220.34M +1.5% 2024 $217.01M +13.7% 2023 $190.93M +2.1% 2022 $187.07M +112.4% 2021 $88.07M +1.2% 2020 $87.02M — Quarterly Long-Term Debt Quarter Ending Long-Term … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Cash and Equivalents of $111.04 million for fiscal year 2025. Xeris Biopharma Holdings, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $111.04M +55.0% 2024 $71.62M +6.2% 2023 $67.45M -44.7% 2022 $121.97M +81.3% 2021 $67.27M +78.9% 2020 $37.60M +92.6% 2019 $19.52M — … Read more
Quick Answer Xeris Biopharma Holdings, Inc. reported Total Assets of $383.53 million for fiscal year 2025. Xeris Biopharma Holdings, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $383.53M +18.7% 2024 $323.06M +0.1% 2023 $322.60M -6.4% 2022 $344.52M +13.2% 2021 $304.36M +91.2% 2020 $159.15M — Quarterly Total Assets Quarter Ending Total … Read more